Effects of Ketamine in Normal and Schizophrenic Volunteers

By A. Lahti, M. Weiler, M. Tamara, A. Parwani, C. Tamminga. Neuropsychopharmacology, 2001

667 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Glutamate and Schizophrenia: Beyond the Dopamine Hypothesis (2006, background): “Lahti et al. (2001) demonstrated that subjects with remitted schizophrenia were quite sensitive to the psychotomimetic effects of infused ketamine and that it brought forward symptoms that were unique to the individual.”
Gamma-band synchronization in the neocortex: novel analysis methods and their application to sensory and motivational systems (2013, background): “An involvement of NMDARs in schizophrenia is suggested by pharmacological studies of human volunteers subjected to non-specific NMDAR antagonists, such as ketamine, and recent postmortem studies on schizophrenic patients (Malhotra et al., 1997; Lahti et al., 2001; Krystal et al., 2003; Gilmour et al”
Ketamine and Ketamine Metabolite Pharmacology: Insights into Therapeutic Mechanisms (2018, background): “5 mM) has also been shown to exacerbate psychotic symptoms in patients suffering from schizophrenia (Lahti et al., 2001).”